Global investment firm Kohlberg Kravis Robert & Co. (KKR) has agreed to invest US$65 million in China Cord Blood Corporation (CCBC), a Chinese umbilical cord blood banking operator. The investment, which will be made through the KKR China Growth Fund, will be used in part to support the company’s business expansion. The transaction represents KKR’s first investment in the healthcare services industry in China.